FDA Is Standardizing PMA Submissions: What Class III Device Manufacturers Should Prepare For
The U.S. Food and Drug Administration (FDA) is continuing its transition toward more structured electronic submissions for medical device premarket review.
In September 2026, FDA issued a new Draft Guidance titled “Electronic Submission Template for Premarket Approval Applications (PMA).”
The guidance introduces the agency’s developing framework for electronic submission templates for Premarket Approval applications and certain PMA supplements.
While the guidance is currently in draft form and is not yet for implementation, it provides an important indication of where FDA’s medical device submission system is heading.
For manufacturers of Class III and other devices requiring PMA approval, now is a good time to understand what this transition may mean for future submissions.
PMA Is Joining FDA’s Broader Electronic Submission Transition
FDA’s move toward electronic submission templates is not new.
Since October 1, 2023, most 510(k) submissions have been required to use FDA’s electronic Submission Template And Resource, commonly known as eSTAR.
FDA has followed a similar path for De Novo Requests, which became subject to electronic submission requirements beginning October 1, 2025.
The newly issued PMA Draft Guidance represents another step in this broader transition.
FDA explains that electronic submission templates are intended to function as guided submission preparation tools, helping improve the consistency of submissions and increase efficiency during FDA review.
In other words, FDA is moving beyond simply receiving regulatory documents electronically.
The agency is increasingly standardizing how regulatory information is organized, presented, and submitted for review.
What Is a PMA?
Premarket Approval, or PMA, is FDA’s most stringent type of medical device marketing application.
PMA is generally required for certain Class III medical devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.
A PMA application generally requires extensive scientific evidence demonstrating reasonable assurance of the device’s safety and effectiveness.
Depending on the device, a PMA may contain substantial documentation involving areas such as:
Device design and technical information
Nonclinical testing
Clinical study data
Biocompatibility
Software and cybersecurity
Sterilization and shelf-life validation
Manufacturing information
Labeling
Risk management
Statistical analysis
Because of the complexity of these applications, the organization and consistency of the submission can be particularly important.
What Is FDA Proposing?
The September 2026 Draft Guidance applies to PMAs and certain PMA supplements submitted to the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER).
According to FDA, the guidance is one of several steps toward developing electronic submission templates that can guide applicants through submission preparation.
Once the guidance is finalized, FDA intends for it to establish:
Standards for submitting PMA information electronically
A timetable for implementation of the electronic submission requirements
Criteria for waivers and exemptions from those requirements
Because the document remains a Draft Guidance, manufacturers should not treat the proposed framework as a currently mandatory PMA submission requirement.
However, companies developing devices that may require a PMA should pay attention to the direction of FDA policy.
Why This Matters for Medical Device Manufacturers
The move toward standardized electronic submissions can have practical consequences well before a PMA is ready to be filed.
1. Submission structure will become increasingly important
PMA applications often contain large volumes of information generated by different teams, laboratories, clinical investigators, manufacturers, and regulatory consultants.
A standardized electronic submission environment places greater importance on organizing this information consistently from the beginning.
Waiting until the final submission stage to organize years of technical and clinical documentation may create unnecessary complications.
2. Internal consistency becomes even more important
Information about the device may appear throughout multiple parts of a PMA.
For example, device descriptions, intended use, indications, specifications, testing parameters, clinical protocols, risk documentation, and labeling may all contain overlapping information.
If those sections are inconsistent, a structured submission format may make discrepancies easier to identify during review.
Manufacturers should therefore maintain strong document control and ensure that critical device information remains consistent throughout the development program.
3. Regulatory planning should begin earlier
For a complex Class III device, PMA preparation should not begin only when clinical testing has been completed.
The eventual submission structure should influence regulatory planning much earlier.
Clinical evidence, nonclinical testing, manufacturing documentation, software documentation, risk management files, and labeling should be developed with the eventual regulatory submission in mind.
4. Electronic submission does not reduce the scientific burden
The move toward electronic templates should not be interpreted as a simplification of PMA requirements.
The fundamental standard remains the same: the applicant must provide sufficient valid scientific evidence to demonstrate reasonable assurance of the device’s safety and effectiveness.
Electronic templates primarily affect how that evidence is organized and submitted, not the level of evidence FDA may require.
What Should Class III Device Manufacturers Do Now?
Manufacturers do not need to immediately restructure existing PMA programs solely because this Draft Guidance has been issued.
However, companies developing devices likely to require PMA approval should consider several practical steps.
First, review whether regulatory, clinical, technical, and quality documentation is being maintained in a structured and consistent format.
Second, ensure that terminology — including the device name, intended use, indications for use, specifications, and key technical characteristics — remains consistent across development documents.
Third, begin organizing testing and clinical evidence according to the eventual PMA submission strategy rather than treating regulatory compilation as a final-stage activity.
Finally, manufacturers should continue monitoring FDA updates as the Draft Guidance moves toward finalization and additional technical resources become available.
The Bigger Picture: FDA Is Standardizing Medical Device Submissions
The PMA Draft Guidance should also be viewed as part of a larger regulatory trend.
FDA has already transitioned 510(k) submissions to a structured electronic format and has implemented electronic submission requirements for De Novo Requests.
PMA is now moving in the same general direction.
For medical device manufacturers, this signals a gradual shift from traditional document compilation toward a more standardized and structured regulatory submission environment.
That makes regulatory readiness increasingly important throughout the product development lifecycle — not simply at the moment an application is submitted.
For companies planning a U.S. market entry for a Class III or other PMA-regulated medical device, understanding the expected FDA submission pathway early can help prevent gaps in evidence, documentation, and regulatory strategy later in development.
Comments